The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases
Open accessPublished version of a preprint
Abstract
Abstract One major hurdle to the success of adoptive T-cell therapy is the identification of antigens that permit effective targeting of tumors in the absence of toxicities to essential organs. Previous work has demonstrated that T cells engineered to express chimeric antigen receptors (CAR-T cells) targeting the murine homolog of the colorectal cancer antigen GUCY2C treat established colorectal cancer metastases, without toxicity to the normal GUCY2C-expressing intestinal epithelium, reflecting structural compartmentalization of endogenous GUCY2C to apical membranes comprising the intestinal lumen. Here, we examined the utility of a human-specific, GUCY2C-directed single-chain variable fragment as the basis for a CAR construct targeting human GUCY2C-expressing metastases. Human GUCY2C-targeted murine CAR-T cells promoted antigen-dependent T-cell activation quantified by activation marker upregulation, cytokine production, and killing of GUCY2C-expressing, but not GUCY2C-deficient, cancer cells in vitro. GUCY2C CAR-T cells provided long-term protection against lung metastases of murine colorectal cancer cells engineered to express human GUCY2C in a syngeneic mouse model. GUCY2C murine CAR-T cells recognized and killed human colorectal cancer cells endogenously expressing GUCY2C, providing durable survival in a human xenograft model in immunodeficient mice. Thus, we have identified a human GUCY2C-specific CAR-T cell therapy approach that may be developed for the treatment of GUCY2C-expressing metastatic colorectal cancer. Cancer Immunol Res; 6(5); 509–16. ©2018 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Several antigens being evaluated as candidates for anti-CRC CAR-T cell therapy have shown efficacy in CRC preclinical models, including carcinoembryonic antigen and guanylyl cyclase 2C [227,228].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,781
Louis, C. U., Savoldo, B., Dotti, G., Pulè, M. A., Yvon, E. S., Myers, G. D., Rössig, C., Russell, H. V., Diouf, O., Liu, E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-354449 · Cited by 1,174
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,073
Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. Μ., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 880
Mulé, J. J., Shu, S., Schwarz, S. L., & Rosenberg, S. A. (1984) · Science · doi:10.1126/science.6332379 · Cited by 688
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 583
Cited by
Sorted by citations
Items 101–143 of 143
Expanded Alternatives of CRISPR–Cas9 Applications in Immunotherapy of Colorectal Cancer
Arroyo-Olarte, R. D., Mejía-Muñoz, A., & León‐Cabrera, S. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00680-z · Cited by 7
CARving up colorectal cancer organoids in vitro
Schürch, C. M. (2019) · Genes and Immunity · doi:10.1038/s41435-019-0079-7 · Cited by 6
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
Rampuria, P., Mosyak, L., Root, A. R., Svenson, K., Agostino, M. J., & LaVallie, E. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-40467-0 · Cited by 5
Li, R., Lin, Y., Shen, X., Guo, J.-Y., Zhang, Y., Tang, J.-D., Xie, L., & Hu, F.-D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1636122 · Cited by 5
Eralp, Y., & Ateş, U. (2023) · Vaccines · doi:10.3390/vaccines11101545 · Cited by 5
Appelbaum, J., Pinto, N. R., & Orentas, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00011-1 · Cited by 5
120 P-MUC1C-ALLO1: An allogeneic car-t for multiple solid tumor indications
Kozłowska, A. K., Zhang, Y., Fritz, J., Wang, S., Codde, R., Argus, E., Ibitokou, S. A., Richardson, V., Jain, S., Richter, M., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0120 · Cited by 5
In vitro assays to evaluate CAR-T cell cytotoxicity
Cao, M., Carlson, R. D., Staudt, R. E., & Snook, A. E. (2023) · Methods in cell biology · doi:10.1016/bs.mcb.2023.05.009 · Cited by 4
Self-citationChimeric Antigen Receptor T-cells (CARs) in Cancer Treatment
Zam, W., & Assaad, A. (2021) · Current Molecular Pharmacology · doi:10.2174/1874467214666210811150255 · Cited by 4
Systemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1425 · Cited by 5
Immunotherapy for precision medicine in colorectal cancer
Cao, M., Xu, M. Y., Bairmani, Z. A., Bashir, B., Waldman, S. A., & Snook, A. E. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2560303 · Cited by 3
Self-citationShen, S., Ruan, Z., Jiang, B., Qiu, W., Zhang, F., & Shu, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1764452 · Cited by 4
Monahan, B. V., Patel, T., & Poggio, J. L. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1761626 · Cited by 3
Molnar, A., Monroe, H. L., Aydin, H. B., Arslan, M. E., Lightle, A. R., Lee, H., & Jabbour, T. E. (2023) · Current Oncology · doi:10.3390/curroncol30020182 · Cited by 3
Pan, W., Zhao, J., Zhang, S., Chen, X., Liang, W., & Li, Q. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108337 · Cited by 3
Granzyme B-based CAR T cells block metastasis by eliminating circulating tumor cellsPreprint
Sun, B., Guo, J., Dong, Y., Hu, Q., Ma, H., Tian, P., Liu, N., Lv, L., Yan, L., Ding, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.18.585442 · Cited by 3
He, J. N., Gao, Y., Sun, Z. S., Li, Y., Wang, J., Zhang, L., & Liu, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1686071 · Cited by 2
γδ T cells in colorectal and liver cancer
Kabelitz, D., & Zeißig, S. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01196-7 · Cited by 2
Flickinger, J. C., Rappaport, J. A., Barton, J. R., Baybutt, T. R., Pattison, A. M., Snook, A. E., & Waldman, S. A. (2021) · Biomarkers in Medicine · doi:10.2217/bmm-2020-0359 · Cited by 2
Self-citation122 Guanylyl cyclase C as a target for CAR-T cell therapy in a metastatic gastric cancer model
Lisby, A., Baybutt, T. R., Weindorfer, M., Carlson, R. D., Zalewski, A., Waldman, S. A., & Snook, A. E. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0122 · Cited by 2
Self-citationPrecision Oncology: Current Status of Targeted Therapies and Prospective Advances
Dhar, S. (2024) · Premier journal of science. · doi:10.70389/pjs.100039 · Cited by 1
Targeting γδ T cells for immunotherapies against colorectal cancer
Mikulak, J., Marzano, P., Cazzetta, V., & Mavilio, D. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.11.009 · Cited by 1
IFNγ-induced antigen loss in chimeric antigen receptor-T cell therapy
Cao, M., Alvarez, J. R., Mitra, R., Xu, M. Y., Baybutt, T. R., Sun, Z., Taylor, O., Doermann, A. S., Staudt, R. E., Waldman, S. A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1772472 · Cited by 1
Self-citationPreclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers
Lü, P., Qiu, S., Pan, Y., Yu, F., & Chen, K. (2021) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.4089 · Cited by 1
Manufacturing of CAR-T Cells: The Assembly Line
Wang, X., & Rivière, I. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_8 · Cited by 1
Li, Y., Li, J., Fu, Y., Zhang, K., Zhu, Y., Shi, Z., & Cao, M. (2022) · Research Square · doi:10.21203/rs.3.rs-1705798/v1 · Cited by 1
CDH17 as a Cell Surface Immunotherapy Target in Colorectal Cancer: An In Silico AnalysisPreprint
Wong, K. K. (2022) · Research Square · doi:10.21203/rs.3.rs-1894271/v1 · Cited by 1
Song, Y., Wang, J. J. J., Zhang, L., An, A. X., Li, H., & Ouyang, D. X. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0738
CAR-T Cell, a Therapeutic Tune-up for Colorectal Cancer Treatment
Neill, K. L. O. (2022) · Novel Approaches in Cancer Study · doi:10.31031/nacs.2022.06.000650
Marsh, R. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_35
The Intestinal Tract Brush Border in Young Children Uniformly Expresses Guanylate Cyclase C
Guglielmo, M. D. D., Holbrook, J., Stabley, D. L., Robbins, K., Boyce, B., Hardy, H., & Adeyemi, A. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001104
Zhang, Y., Lin, S., Xiao, Z., & Ho, M. (2024) · Proteoglycan Research · doi:10.1002/pgr2.70004
Therapeutic role of immune cells against colon cancer
Gupta, M. K., Gouda, G., & Vadde, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00003-4
Jin, K.-T., Chen, B., Liu, Y.-Y., Lan, H. U.-R., & Yan, J.-P. (2021) · Figshare · doi:10.6084/m9.figshare.14432549
Could GUCY2C-targeted pharmacotherapy be effective in treating colorectal cancer?
Waldman, S. A., & Snook, A. E. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2636120
Self-citationKroemer, M. (2018) · theses.fr (ABES) · doi:10.70675/f4ebb828z8a7ez47e9zbb78z4453ed026df3
Sun, B., Guo, J., Yang, D., Hu, Q., Ma, H., Tian, P., Liu, N., Lv, L., Yan, L., Ding, H., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03797-7
Defying inflammation-driven early-onset colorectal cancer: predict, prevent, and personalize
Samuel, T. M., Samuel, S. M., Varghese, E., Sreenesh, B., & Büsselberg, D. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.05.005
Yang, Y., Gao, Z., Song, P., Wang, C., Wang, K., Xi, Z., & Jing, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1829723
Bartolini, M., Algaze, S. D., & Lenz, H. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108304
Doermann, A. S., Caspi, A., Evans, A. E., Feci, A., Entezari, A. A., Snook, A. E., & Waldman, S. A. (2026) · Cancer Biology & Therapy · doi:10.1080/15384047.2026.2683096
Self-citationZhu, P., He, L., Du, X., Pang, P., Ji, Z., Yang, Y., Cao, F., & Wang, Q. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261473054
Su, K., Tan, Z., Li, H., You, K., Xiao, S., Chen, H., Li, D., Liu, X., Du, X., Hu, J., et al. (2026) · BioFactors · doi:10.1002/biof.70150
Metadata
- Authors
- Magee, M. S., Abraham, T. S., Baybutt, T. R., Flickinger, J. C., Ridge, N. A., Marszalowicz, G. P., Prajapati, P., Hersperger, A. R., Waldman, S. A., & Snook, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Drexel University (US)
- Corresponding author
- Snook, Adam E.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2018-04-30
- Volume
- 6
- Issue
- 5
- Pages
- 509-516
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC5932207
- OpenAlex
- W2796020321
- Cited by
- 143
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 15 · 2023: 23 · 2022: 31 · 2021: 22 · 2020: 14 · 2019: 10 · 2018: 5
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Medicine Forum (submittedVersion)
- Funders
- NIH (P30 CA56036, R01 CA204881, R01 CA206026, F31 CA171672)
- Pennsylvania Department of Health (SAP #4100059197, SAP #4100051723)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- GUCY2C, chimeric antigen receptor T cells, CAR T-cell therapy, colorectal cancer metastasis, lung metastasis, scFv, tumor antigen targeting, intestinal epithelium, xenograft models, adoptive T cell therapy
- MeSH terms
- Receptors, Enterotoxin, Receptors, Chimeric Antigen, Animals, Cells, Cultured, Cytotoxicity, Immunologic, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Transgenic, Neoplasm Metastasis, Receptors, Antigen, T-Cell, T-Lymphocytes, Colorectal Neoplasms, Immunotherapy, Adoptive, Xenograft Model Antitumor Assays, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
